
Ubigene gene knockout cell lines mediated by optimized CRISPR-Cas9 technology provide reliable in vitro models for investigating gene function, signaling pathways, disease mechanisms, and therapeutic targets.
GALNS (galactosamine (N-acetyl)-6-sulfatase) encodes a lysosomal exohydrolase required for degradation of the glycosaminoglycans keratan sulfate and chondroitin 6-sulfate. The enzyme catalyzes removal of sulfate groups during lysosomal glycosaminoglycan catabolism, contributing to normal turnover of these extracellular matrix-associated polysaccharides. GALNS therefore plays an essential role in lysosomal substrate degradation and glycosaminoglycan metabolism.
A human gastric carcinoma cell line established from a metastatic lymph node. It was originally derived from gastric cancer and described as an undifferentiated, mucin-producing tumor cell line.
Each knockout cell line is validated by STR authentication, sterility testing (bacteria/fungi), and mycoplasma screening. Genotype is confirmed by two rounds of PCR and Sanger sequencing. Only clones that pass all QC criteria are released, ensuring reliable identity and performance for downstream applications.

Cas9 cell lines in our cell bank can stably express Cas9 protein. Each Cas9 Stable Cell Line is easy to use and enables gene knockout simply by transfecting gRNA, while transfection of gRNA and donor DNA results in gene knock-in or point mutations
These Cas9 stable cell lines have been used to construct the KO cell lines for various genes, gene KO efficiency 5-10 times improved.
Selected cells, low passages, good cell condition, high activity, applicable for all kinds of gene-editing experiments.

Targeted knockout region: EExon 5
Reference Transcript: NM_000512
Frameshift Mutation Strategy
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use






Simply fill out the form below to leave your inquiry
— we will respond within 24 Hours
* Name
* Institution
* Products & Services of Interest
If email is not available, how else can we reach you?
How did you hear about us?